Saturday 17 October 2026 Export AORT’s income statement to Excel — free account

Artivion, Inc.

Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.3%, EPS fell 1,033.3%, free cash flow fell 202.5% and total debt rose 67.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five, operating cash flow growth for three.

21.78 0.09 −0.41%

Follow AORT

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: 142×
Dividend yield: —
F-score: 7/9
Altman Z: 3.73
Beneish M: −2.38
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 20.73

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	16	5	—	6	12	—	—	1	—	4	2	—

Insider Ownership 4.91%

Capital & Financial Ratios $m

Market Cap 1,070.00

Revenue 471.47

Net Income (3.16)

Free Cash Flow (9.16)

Net Debt 288.91

Current Ratio 3.47

Debt/Equity 0.82

P/E ratio 0.00

Fwd P/E 142.00

P/S ratio 2.24

P/B ratio 2.37

Past 5Y EPS Growth —

This Y EPS Growth (228.57%)

Next Y EPS Growth 206.94%

Next Y revenue growth 11.12%

Next 5Y EPS Growth 30.11%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.40%

10-year low 10-year high

P/B against its own 10 years 23.15%

10-year low 10-year high

EV/Sales against its own 10 years 17.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	59	53	65	77
Receivables	74	86	104	111
Inventory	82	80	92	103
Other	—	—	—	—
	281	290	358	371

	2023	2024	2025	Q'26
Payables	13	18	16	21
ST’ Debt	1	0	—	—
Other	2	1	25	32
	58	67	102	107

Compound Annual Growth %

	10y	5y	3y
Sales	11.70%	11.75%	12.04%
Cash Flow	13.30%	26.38%	0.00%
Earnings	9.55%	0.00%	0.00%
Book Value	11.19%	6.40%	16.38%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	116	126	—	—	—
’25	99	113	113	116	441
’24	97	98	96	97	389
’23	83	89	88	94	354
’22	77	80	77	79	314
’21	71	76	72	79	299
’20	66	54	65	68	253

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	(1)	—	—	—
’25	(17)	15	22	20	40
’24	(5)	6	11	10	22
’23	(6)	7	7	11	19
’22	(1)	(8)	4	0	(5)
’21	(3)	3	(3)	1	(3)
’20	3	(3)	8	5	12

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(12)	—	—	—
’25	(21)	12	18	(8)	1
’24	(9)	4	8	9	11
’23	(10)	5	5	8	9
’22	(3)	(10)	0	(6)	(18)
’21	(5)	(3)	(7)	(2)	(17)
’20	0	(5)	6	2	4

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.03	(0.28)	—	—	—
’25	(0.01)	0.03	0.13	0.05	0.21
’24	0.18	(0.05)	(0.05)	(0.39)	(0.32)
’23	(0.33)	(0.08)	(0.24)	(0.10)	(0.75)
’22	(0.08)	(0.11)	(0.34)	0.05	(0.48)
’21	(0.08)	(0.06)	0.26	(0.51)	(0.38)
’20	(0.18)	(0.10)	(0.08)	(0.09)	(0.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.94	14.03	16.80	20.76	12.63	16.95	9.64	11.44	16.48	21.97	Analyst estimates 2026–2028 Powerpack
	High	20.15	24.00	36.05	33.00	31.77	32.34	23.43	19.00	30.45	48.25
People
People	Employees	665	1,000	1,100	1,200	1,200	1,300	1,300	1,500	1,600	1,800
	Revenue/emp, $m	0.27	0.19	0.24	0.23	0.21	0.23	0.24	0.24	0.24	0.25
Income, $m
Income, $m	Revenue	180	190	263	276	253	299	314	354	389	441
	Gross margin, %	65.92	67.81	65.81	66.26	66.26	66.09	64.54	64.74	64.03	64.40
	EBT	18	4	(6)	2	(17)	(15)	(15)	(22)	(8)	15
	EBT margin, %	10.21	1.88	(2.43)	0.60	(6.78)	(4.96)	(4.78)	(6.10)	(1.93)	3.35
	Net income	11	4	(3)	2	(17)	(15)	(19)	(31)	(13)	10
	Depreciation	8	10	18	18	21	24	22	23	24	22
Per share, $
Per share, $	Revenue	5.66	5.75	7.22	7.44	6.69	7.67	7.84	8.69	9.32	9.73
	Earnings	0.33	0.11	(0.08)	0.05	(0.44)	(0.38)	(0.48)	(0.75)	(0.32)	0.22
	Cash flow	0.62	0.33	0.27	0.43	0.33	(0.07)	(0.13)	0.46	0.53	0.88
	Capex	(0.19)	(0.20)	(0.16)	(0.22)	(0.22)	(0.36)	(0.31)	(0.24)	(0.27)	(0.86)
	Free cash flow	0.42	0.13	0.11	0.21	0.10	(0.43)	(0.44)	0.22	0.27	0.02
	Book value	6.56	8.39	7.55	7.70	8.68	7.71	7.10	6.92	6.63	9.89
	Shares, m	32	33	36	37	38	39	40	41	42	45
Valuation, ×
Valuation, ×	P/E	57.58	173.64	0.00	583.84	0.00	0.00	0.00	0.00	0.00	217.19
	P/S	3.36	3.32	3.93	3.64	3.53	2.65	1.50	2.07	3.07	4.69
	P/B	2.90	2.28	3.76	3.52	2.72	2.64	1.66	2.60	4.31	4.61
	EV/Sales	3.43	4.30	4.62	4.32	4.46	3.52	2.37	2.78	3.75	5.03
	EV/FCF	45.82	195.52	296.45	153.76	223.94	(58.43)	(38.32)	189.92	203.47	(726.43)
Cash, $m
Cash, $m	Operating cash flow	20	11	10	16	12	(3)	(5)	19	22	40
	Capex	(6)	(7)	(6)	(8)	(8)	(14)	(12)	(10)	(11)	(39)
	Free cash flow	14	4	4	8	4	(17)	(18)	9	11	1
Balance, $m
Balance, $m	Working capital	117	136	145	142	174	203	198	223	223	257
	Total debt	72	226	223	221	297	313	312	310	317	218
	Net debt	14	185	181	187	235	258	272	251	264	153
	Shareholders’ equity	209	277	275	286	329	301	284	282	276	448
Returns, %
Returns, %	ROA	4.25	0.80	(0.48)	0.29	(2.38)	(1.86)	(2.45)	(3.93)	(1.69)	1.17
	ROIC	6.11	1.08	1.28	2.25	0.27	0.91	0.70	0.67	4.50	3.51
	ROE	5.80	1.50	(1.02)	0.61	(5.39)	(4.68)	(6.53)	(10.80)	(4.78)	2.69

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
Median of peers	$1.1B	—	26.1×	+4.77%	—	−6.38%	63.83%	3.80%

All 149 Medical Devices stocks →

Artivion, Inc. (AORT) key facts

Strength: Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024.
Artivion, Inc. (AORT) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, AORT traded at $21.78, a market capitalization of $1.1 billion.
Return on equity was 2.69% and debt-to-equity 0.82.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.73 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.